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Background/aim: Hypoxia-induced pulmonary arterial hypertension (PAH) is characterized by prostacyclin (PGI2) disorder, which
manifests in the same manner as in monocrotaline (MCT)-induced PAH. Endogenous PGI2 inhibitor coupling factor 6 (CF6) is involved
in MCT-induced PAH. This study aimed to explore the presence or absence of a correlation between hypoxia-induced PAH and CF6.
Materials and methods: This study was conducted between January 2019 and June 2020. A total of 135 male Wistar rats (aged 8 weeks
and weighing 200–250 g) were randomly divided into five groups: (A) control, (B) 1 week of hypoxia, (C) 2 weeks of hypoxia, (D) 3
weeks of hypoxia, and (E) 4 weeks of hypoxia. CF6 expression in both lung tissue and blood samples from the lung vasculature and tail
vein was measured by western blotting, immunohistochemistry, reverse transcription polymerase chain reaction, and enzyme-linked
immunosorbent assay.
Results: Hemodynamic and morphological changes in hypoxia-induced rats indicated PAH development. The results showed the
presence of a correlation between the mRNA and protein levels of CF6 in lung tissue, activity of mitochondrial ATP synthase, and
hypoxia time, and there was a significant increment in the group exposed to hypoxia for 4 weeks compared to the control group. The
decrement expression of ATPase inhibitory factor 1 (IF 1) mRNA was consistent with the outcomes of ATP synthase activity in lung
tissue in the 4 weeks of hypoxia group compared with the control group. However, the levels of CF6 and ATP synthase activity did not
differ between blood samples from the lung vasculature and tail vein.
Conclusion: In hypoxia-induced PAH, CF6 showed downregulated expression in lung tissue, but not in pulmonary vasculature and
circulation. Therefore, we speculated that CF6 and ATP synthase may play important roles in hypoxia-induced PAH.
Key words: Coupling factor 6, adenosine triphosphate synthase activity, hypoxic, pulmonary arterial hypertension

1. Introduction
Pulmonary arterial hypertension (PAH), a fatal disease
with sustained increased pulmonary vascular resistance
and abnormal pulmonary vascular remodeling, eventually
leads to right-sided heart failure and death. Pathological
changes in PAH include destruction of pulmonary
vascular cell homeostasis and extensive vascular disease.

Over the past several decades, significant progress has
been made in the symptomatic relief of PAH, including
the use of endothelin receptor antagonists, vasodilators,
and phosphodiesterase inhibitors. However, these
approaches do not improve the overall survival rate [1].
Benza et al. demonstrated that the five-year survival rates
of patients has remained at 57% [2]. The high morbidity
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and mortality caused by PAH are still unacceptable [3],
and new treatment regimens are needed.
The 6th World Symposium on Pulmonary Hypertension
proposed that the hemodynamic definition of PAH
should be changed to a mean pulmonary artery pressure
(mPAP) of > 20 mmHg [4]. Pathological lesions typically
present in PAH patients upon clinical presentation, such
as pulmonary artery medial hypertrophy, adventitial
thickening, or neointimal proliferation [5]. However,
the mechanisms underlying these pathological lesions
are not completely understood. Abnormal proliferation
and secretion of endothelial cells in PAH increases the
synthesis of vasoconstrictors and decreases the synthesis of
vasodilators. PAH patients show enhanced levels of potent
vasoconstrictors and impaired synthesis of vasodilatory
factors, such as prostacyclin (PGI2) [6,7].
Coupling factor 6 (CF6), an essential subunit of the stalk
of mitochondrial Adenosine triphosphate (ATP) synthase,
was recently identified as a novel endogenous inhibitor of
PGI2 [8]. This is important because the PGI2 pathway is
currently a major target for PAH treatment. CF6 can be
released into the blood as a circulating vasoconstrictive
peptide after vascular endothelial cells experience
mechanical forces, stress, hypoxia, or high glucose levels
[9,10]. In addition, the levels of CF6 have been shown to
markedly increase in rats with lung disease [11,12]. Our
previous experiments have also demonstrated that CF6 was
increased in monocrotaline (MCT)-induced PAH and that
the inhibition of CF6 alleviated PA remodeling in rats [13].
These results demonstrated the critical role of CF6 in the
pathogenesis of MCT-PAH. Hypoxia-induced PAH is also
characterized by PGI2 disorder and PA vasoconstriction
and remodeling; however, it is mechanically different from
MCT-induced endothelial injury. As an endogenous PGI2
inhibitor, CF6 may play an important role in hypoxiainduced PAH.
Our previous experiments showed that CF6 was
markedly increased in MCT-induced PAH rat models and
that the inhibition of CF6 alleviated PA remodeling. The
pathophysiological mechanism of PAH caused by MCT
differs from that observed in clinical settings. Therefore,
we explored the potential role of ATP synthase-CF6 in
hypoxia-induced PAH.
2. Material and methods
2.1. Animal models
The animal study was conducted between January 2019
and June 2020 [14]. One hundred and thirty-five male
Wistar rats (aged 8 weeks and weighing 200–250 g)
were obtained from the Beijing Vital River Laboratory
Animal Technology Co., Ltd. The rats were housed in
a standard animal room at a temperature of 21 ± 1 °C,
humidity of 55% ± 5%, and 12-h light/dark cycle with free

access to water and food. All experimental protocols and
procedures used in this study were approved by the Animal
Care Committee of Shandong University Affiliated with
Qianfoshan Hospital (protocol number: S 030). This study
was in accordance with the “Guidelines for the Care and
Use of Laboratory Animals” from the National Institutes
of Health (NIH Publications No. 8023, revised 1978).
Rats were randomly assigned to one of five possible
groups according to the amount of time under hypoxic
conditions: group A (n = 15) was the control group;
group B (n = 30) included rats exposed to hypoxia (kept
in normobaric hypoxia [10% O2] by establishing a setpoint of 10% O2 in the oxygen controller with N2 tank and
allowed the system to reach a steady state [XBS-03]) for 1
week; group C (n = 30) included rats exposed to hypoxia
for 2 weeks; group D (n = 30) included rats exposed to
hypoxia for 3 weeks; and group E (n = 30) included rats
exposed to hypoxia for 4 weeks [15].
All animals were monitored daily until they developed
symptoms of PH, such as weight loss and tachypnea.
At weeks 1, 2, 3, or 4, animals were anaesthetized using
sodium pentobarbital (30 mg/kg) and intubated using
a small animal ventilator (HX-300S; Chengdu TME
Technology Co., Ltd., China) at a rate of 60 breaths/min
and a tidal volume of 1.1–1.3 mL/100 g. Hemodynamic,
morphologic, and biochemical assessments were
performed.
2.2. Echocardiography and hemodynamic measurements
The rats in the experimental groups were anesthetized
with an intraperitoneal injection of sodium pentobarbital
(30 mg/kg). Room temperature was maintained at
approximately 25 °C. Cardiac function was evaluated
using a Visual Sonics Vevo 770 echocardiographic
machine (Visual Sonics, Toronto, Canada) equipped with
a 14-MHz linear transducer. An echocardiographic expert
(Y.J.) performed measurements in a blinded manner.
Short- and long-axis B-dimensional parasternal views of
both ventricles at the level of the papillary muscles were
acquired to visualize the left ventricle (LV) and right
ventricle (RV). Pulmonary artery pressure transduction
was conducted with the right jugular vein using a 1.4-F
Millar Mikro-Tip catheter transducer (Millar Instruments
Inc., Houston, TX, USA) directed to the main pulmonary
artery after insertion into the right ventricular outflow
duct, although RV systolic pressure (RVSP) was detected
with a power laboratory monitoring device (Miller
Instruments). Hemodynamic values were accurately
computed the LabChart 7.0 physiological data acquisition
system (AD Instruments, Sydney, Australia).
2.3. Tissue processing and histology
After performing the above tests, cardiac arrest was
induced using an overdose of sodium pentobarbital
(160 mg/kg body weight). After thoracotomy, the entire
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lung was excised. The left lung was removed and frozen
in liquid nitrogen, and the right lung was inflated with
0.5% low-melting agarose at a constant pressure of 25 cm
H2O and then fixed in 10% formalin for 24 h. Next, the
heart was isolated. The weight ratio of the right ventricle
to the left ventricle plus the septum (RV/[LV + S]) was
determined using Fulton’s index [16].
2.4. Western blot
Western blot analysis was performed using a Protein
Extraction Kit (Beyotime Institute of Biotechnology,
Jiangsu, China) to isolate proteins, and protein
concentration was measured using a bicinchoninic acid
(BCA) protein assay reagent kit (Pierce) [17].
The same amount of total protein (60 μg) was applied
to each lane of a sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) (5%–12%) and then
transferred onto a polyvinylidene difluoride (PVDF)
membrane. The membranes were then blocked with 5%
nonfat dry milk in phosphate buffer solution Tween 20
(PBS, T, containing 0.05% Tween 20), and then incubated
overnight at 4 °C with primary antibodies against CF6
(Abcam, MA, USA, 1:1500) and α-smooth muscle actin
(α-SMA) (Abcam, MA, USA, 1:1500). Subsequently, blots
were developed using an enhanced chemiluminescence
(ECL) detection kit (Millipore, Merck, Germany). Images
were visualized using a FluorChem E Imager (ProteinSimple, Santa Clara, CA, USA). α-SMA can indicate
the severity of pulmonary vascular muscularization.
Measurements to determine relative densities were
normalized to that of a standard protein (GAPDH)
(Proteintech, Wuhan, China) using NIH Image J software.
2.5. ELISA
After high-dose pentobarbital administration, the blood
samples obtained from the tail vein and pulmonary
vasculature were stored at room temperature for 1 h
and were then centrifuged at 3000 rpm at 4 ℃ for 15
min. Plasma samples were collected and stored at −80
℃. Lung tissue from the left lung was kept at 4 ℃ for
12 h and then at room temperature for 1 h. Lung tissue
was rinsed with normal saline. After grinding, the
homogenate was adjusted using PBS at a rate of 10%. The
supernatant was centrifuged at 5000 × g at 4 ℃ for 15
min. CF6 levels in blood samples from the tail vein and
pulmonary vasculature were measured using enzymelinked immunosorbent assay (ELISA) performed with
a commercial enzyme immunoassay kit (EIA Assay
Design, Inc.; Ray Biotech, Norcross, GA) according to
the manufacturer’s instructions. The amount of CF6 was
expressed in picograms per milliliter of protein.
2.6. Determination of mitochondrial ATP synthase activity
Mitochondria were isolated from rat lung tissues using a
mitochondrial isolation kit (Abcam, MA, USA, ab110168).
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ATP synthase activity was assayed spectrophotometrically
using a microplate assay kit (Abcam, MA, USA,
#ab109714) according to the manufacturer’s instructions.
2.7. Reverse transcription polymerase chain reaction
(RT-PCR)
ATPase inhibitory factor 1 (IF1) is a physiological
endogenous inhibitor of ATP synthase. IF1 inhibits the
synthetase and hydrolase activities of ATP synthase. Many
recent studies have shown that IF1 plays an important role
in stabilizing the structure of ATP synthase in normoxic
environment [18–20]. To examine whether the changes in
IF1 and ATP synthase in hypoxic environments are the
same, we measured the mRNA expression level of IF1 in
lung tissue. Total RNA was extracted from the lung tissues
using TRIzol reagent (Invitrogen, Germany). cDNA
was synthesized from 1 μg RNA using a Prime Script
RT Reagent Kit (Vazyme, Nanjing, China), as described
previously. mRNA expression was determined using
gene-specific primers and SYBR Green (SYBR Green Gel
Dye) using a Bio-Rad iQ5 Multicolor Real-Time PCR
machine (Bio-Rad Laboratories, USA). For each sample,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and the target gene were amplified in triplicate in separate
tubes. Relative gene expression was calculated using the
2-ΔΔCT method [21] and normalized to GAPDH expression.
The primers used in this study were as follows:
GAPDH (forward, 5′-AGATCCACAACGGATACATT-3′;
reverse, 5′-TCCCTCAAGATTGTCAGCAA-3′),
α-SMA (forward, 5′-CCGACCGAATGCAGAAGGA-3′;
reverse, 5′-ACAGAGTATTTGCGCTCCGGA-3′),
CF6 (forward, 5′-TCAGTGCAAGTACCACAGACTC-3′;
reverse 5′- CACAGAGACTGCTGACCGAA-3′),
and IF-1 (forward, 5′- CGGACTCGTCGGAGAGCAT-3′;
reverse 5′- TTCTCTCGTTTCCCGAAGGC-3′).

2.8. Immunohistochemistry
The right lung lobes were cut and processed as previously
described by preparing standard formalin-fixed, paraffinembedded tissues for HE or regular immunohistochemical
staining [22]. The tissue samples were sectioned at a
thickness of 5 μm [23]. Immunohistochemical analysis
involved incubation of the sections with the primary
antibody, anti-α-SMA (1:200; Abcam), followed by
incubation with a biotinylated secondary antibody, and
use of the avidin-biotin complex technique with Vector
Red substrate (Vector Laboratories, USA). All images
were obtained using an Olympus (Olympus Corporation,
Japan) LCX100 Imaging System and analyzed using ImageJ
software (version 1.38x; National Institutes of Health) by
an expert (L.Y.). In each lung section, small pulmonary
arteries (PAs) (50–100 μm in diameter) were analyzed
at × 40 magnification in a blinded manner. Medial wall
thickness was expressed as the summation of two points of
medial thickness/external diameter × 100 (%). Intraacinar
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(precapillary) PAs (20–30 μm in diameter, 25 vessels each)
were assessed for occlusive lesions and rated as follows:
grade 0, no evidence of neointimal lesions; grade 1, less
than 50% luminal occlusion; and grade 2, more than
50% luminal occlusion [24]. There was no evidence of
neointimal lesion formation in any PAs from control rats
(all PAs were grade 0).
2.9. Statistics
The data are presented as mean ± standard error of
the mean (SEM). The values from the two groups were
compared using the unpaired t-test. Analysis of variance
(ANOVA) was used to compare multiple groups.
Subsequently, the Newman–Keuls test was performed.
All analyses were performed using SPSS (version 17.0,
SPSS Inc. Chicago, IL, USA). Results were considered
statistically significant at p < 0.05.
3. Results
3.1. Hemodynamic and morphologic changes in hypoxiaexposed PAH rats
After four weeks of hypoxia exposure, the skin of the rats
lost its luster and became very rough, and the degree of
dyspnea worsened. Pulmonary vascular remodeling was
evaluated by measuring the wall thickness of pulmonary
arterioles. After exposure to hypoxia, hemodynamic
(Figure 1a) and morphological (Figure 1b) changes were

analyzed at 1, 2, 3, and 4 weeks. RVSP was significantly
increased in the 3- and 4-week hypoxia exposure groups
compared with that in the other study groups. There
were no significant changes observed in the 1- or 2-week
hypoxia exposure groups relative to the control group
(p < 0.05, Figure 1c). The rats also developed the same
increase in right ventricular hypertrophy after 3 weeks of
exposure in both the 3- and 4 -week exposure group. This
was confirmed by the RV/(LV + S) ratio (p < 0.05, Figure
1d).
The same trend was observed in morphological and
hemodynamic changes. Hematoxylin-eosin staining
indicated that the wall thickness of vessels was significantly
increased in the hypoxia group in a time-dependent
manner (Figure 2a). Immunohistochemical analysis
revealed increased α-SMA immunostaining in the lung
tissue of the hypoxia-induced group over time (Figure 2b).
The ratios of vascular medial thickness (i.e. smooth muscle
thickness) to outer diameter (total vessel wall thickness)
of the small pulmonary arteries (diameter 50–100 μm)
and the vascular occlusion score of the small pulmonary
arteries (diameter 20–30 μm) in different groups also
validated PAH (Figure 2c, Figure 2d).
3.2. CF6 level in hypoxia-induced PAH
The expression of CF6 in lung tissue and blood samples
from the tail vein of hypoxia-induced PAH rats was

Figure 1. Hemodynamic changes in hypoxia-exposed rats. (A, C) RVSP
was significantly increased in the 3- and 4-week exposure groups. (B,
D) Rats developed the same elevated right ventricular hypertrophy after
3 weeks of exposure. The data represent the mean ± SEM. *p < 0.05.
(RVSP, right ventricle systolic pressure; con, control; 1w, 1-week hypoxia
group; 2w, 2-week hypoxia group; 3w: 3-week hypoxia group; 4w: 4-week
hypoxia group).
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examined. Western blotting results for CF6 showed that no
significant change was observed in the first 3 weeks, but an
almost half-fold change appeared in the 4-week hypoxia
group compared with that in the control group (p < 0.05,
Figure 3a). Western blot analysis of α-SMA confirmed
a 1.7-fold change in CF6 during the development of
hypoxia-induced PAH (Figure 3b). Reverse transcription
Polymerase Chain Reaction (RT-PCR) was performed to
further confirm the mRNA levels of CF6 and showed a
significant decrease in the 4-week hypoxia group relative
to the control group (p < 0.05, Figure 3c). The level of CF6
in lung tissue was downregulated in a time-dependent
manner, and more than a half-fold change was observed
in the 4-week hypoxia group relative to the control group
(p < 0.05, Figure 3d). The level of CF6 in blood samples
from the tail vein (Figure 3e) and the lung vasculature
(Figure 3f) was also analyzed to determine its expression.
However, there were no significant difference in CF6
levels in blood samples or the lung vasculature in the
4-week hypoxia exposure group compared with those in
the control group.

3.3. Mitochondrial ATP synthase activity and CF6 level
CF6 is an essential subunit of mitochondrial ATP synthase
that is released into the blood to affect vascular function
as a circulating vasoconstrictive peptide. Therefore, we
analyzed ATP synthase activity to clarify the relationship
between CF6 and mitochondrial ATP synthase. The
mitochondrial ATP synthase activity in local lung tissue
was downregulated in a time-dependent manner and
showed a significant decrease only after 4 weeks of hypoxia
(Figure 4a). No significant change in ATP synthase activity
was observed in the circulatory level in blood samples
from the tail vein (Figure 4b).
3.4. Local IF1 level in rats with hypoxia-induced PAH
IF1 is a key regulator of ATP synthase and its subunits,
such as CF6. To investigate the influence of IF1 in hypoxic
conditions, we examined the expression of IF1 mRNA. The
IF1 mRNA expression in lung tissue was significantly lower
after four weeks of hypoxia and showed a half-fold change
in the 4-week hypoxia group relative to the control group
(p < 0.05, Figure 4c). This result is consistent with the ATP
synthase activity in lung tissue result, but is contrary to the
ATP synthase activity in blood samples from the tail vein.

Figure 2. Morphological changes in hypoxia-exposure rats. (A) Hematoxylin and eosin staining. (B) IHC
staining for α-SMA antibody. (C) Ratios of vascular medial thickness (i.e. smooth muscle thickness) to the outer
diameter (total vessel wall thickness) of small pulmonary arteries (diameter, 50–100 μm) in different groups. (D)
Vascular occlusion score of the small pulmonary arteries (diameter, 20–30 μm) in different groups. Data are the
mean ± SEM. *p < 0.05 compared with the control group. (con, control; 1w, 1-week hypoxia group; 2w, 2-week
hypoxia group; 3w: 3-week hypoxia group; 4w: 4-week hypoxia group).
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Figure 3. The local expression of CF6 in PAH-induced by hypoxia. The protein level of (A) CF6
and (B) α-SMA were measured in total lung homogenates from PAH rats using western blot. (C)
The mRNA level of lung CF6 was measured using RT-PCR. The level of CF6 in lung tissue (D),
blood sample in tail vein, (E) and lung vasculature was measured using ELISA. Data are shown
as the mean ± SEM, *p < 0.05 compared with control group (con, control; 1w, 1-week hypoxia
group; 2w: 2-week hypoxia group; 3w: 3-week hypoxia group; 4w: 4-week hypoxia group).

Figure 4. ATP synthase activity expression level in the lung tissue(A) and tail vein
blood sample (B) was measured using a microplate assay kit. (C) Expression level of
IF1 in lung tissue following hypoxia exposure. Data are shown as the mean ± SEM,
*p < 0.05 compared with the control group. Data are shown as the mean ± SEM, *p
< 0.05 compared with the control group (con, control; 1w, 1-week hypoxia group;
2w: 2-week hypoxia group; 3w: 3-week hypoxia group; 4w: 4-week hypoxia group).
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Figure 5. A flow diagram for the experiment steps.

4. Discussion
This study was designed to investigate the role of CF6
in different PAH types. Unlike the increased expression
of CF6 in MCT-induced PAH, the expression of CF6
in hypoxia-induced PAH had a different profile. This
interesting and unexpected finding demonstrated: 1) in
hypoxic PAH, the gene and protein levels of CF6 in lung
tissue were significantly lower; 2) no significant change in
CF6 levels was observed in blood samples from the tail
vein or lung vasculature in hypoxia-induced PAH; and 3)
the local mitochondrial ATP synthase activity in the lung
tissue showed a significant decrease only after four weeks
of hypoxia. No significant changes in mitochondrial ATP
synthase activity in blood samples from the tail vein were
found.
Significant changes in hemodynamics and morphology
confirmed the development of PAH in rats under hypoxic
conditions. The expression of α-SMA in the lung tissue
of rats exposed to hypoxia was significantly higher,
indicating abnormal proliferation of the pulmonary
vascular smooth muscle. The etiology of PAH is complex.
Hypoxia-induced PAH is characterized by continuously
increased pulmonary artery pressure, pulmonary vascular
resistance, and RV hypertrophy [25]. Inflammation and
smooth muscle cell proliferation may play key roles in this
disease. The hypoxia animal model has been widely used
to study PAH [26]. We successfully established a model of
hypoxia-induced PAH, as demonstrated by the increase
in RVSP and proliferation of pulmonary arterial smooth
muscle cells (PASMCs).
At present, it is unclear whether the increase in CF6
levels in PAH is related to pulmonary constriction induced
by PGI2 inhibition. Studies have confirmed that CF6 levels
are increased in MCT-induced PAH and appear to play
an important role in the disease process [27]. This study
found no indication of elevated CF6 levels in hypoxic PAH.
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Endothelial cell injury is common in all metabolic
diseases and MCT-induced diseases. Circulating levels of
CF6 increase after endothelial injury. CF6 is produced in
the cytoplasm in an immature form (amino acids 1–108)
and released into the extracellular matrix in the mature
form (amino acids 33–108) after enzymatic deletion of the
signal peptide (amino acids 1–32) [28]. CF6 can bind to
the subunit of ATP synthase, as ectopic ATP synthase, to
accelerate proton import and induce intracellular acidosis
[8,12]. Moreover, CF6 can increase blood pressure and
enhance angiotensin II-induced vasoconstriction in small
arterioles [9,10]. Considerable evidence suggests that
CF6 plays an important role in many diseases such as
hypertension [29], diabetes mellitus [30], acute myocardial
infarction [31], and stroke [32]. In our previous study, local
and circulating levels of CF6 were significantly increased
in rats with MCT-induced PAH [27].
However, this study found no increase in CF6
expression in blood samples from the tail vein or lung
vasculature in hypoxic PAH patients. The mechanism
underlying hypoxic PAH is completely different from
that of MCT-induced PAH. Hypoxic inhalation without
direct cell damage showed no increase in CF6 levels.
Because CF6 is localized to the surface of endothelial cells
and is released mainly by endothelial cells, we can infer
that hypoxia-induced PAH initially causes little injury
or rupture of endothelial cells. Hypoxia is a strong stress
signal, and the first response organ is the intratracheallung tissue pathway. The changes in CF6 found in the local
lung tissue are rational. Oxygen supply closely influences
ATP synthesis, and CF6 is an essential component of the
stalk of mitochondrial ATP synthase, and it is also released
from the cytoplasm to the cell membrane [10,33]. In this
study, lung tissue CF6 levels may be modulated by hypoxic
stimuli. Furthermore, because of negative regulation by
the vasoconstrictor, CF6, we speculate that stress from
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hypoxia may suppress ATPase and its subunit expression.
Our study did indeed indicate a decrease in ATP synthase
activity. ATP synthase is a multi-subunit membranebound enzyme of the mitochondria that synthesizes ATP
via the proton electrochemical gradient produced by
the respiratory chain [34]. The activity of ATP synthase
regulates oxidative phosphorylation, and cell death
[35,36]. Mitochondrial ATP synthase is the fifth and final
component of the oxidative phosphorylation chain [37].
ATP plays a crucial role in adenosine triphosphate (ATP)
generation and acts as a chemical fuel for life processes
[38]. However, the mechanism of CF6 decrease in hypoxic
lung tissue may require further investigation.
ATPase IF1 is a physiological endogenous inhibitor
of ATP synthase. IF1 inhibits both the synthase and
hydrolase activity of the ATP synthase [39,40]. Walker et
al. proposed that IF1 interacts with F1 of the ATP synthase
enzyme to inhibit its function [41]. Many recent studies
have indicated that IF1 plays important roles in normoxia,
such as the inhibition of cell apoptosis, stabilization of
the F1F0-ATPase structure, and inner mitochondrial
membrane cristae structure [18–20]. In many cancers, IF1
is present at higher levels in the brain, colon, ovary and
other organs [42–44]. However, the mRNA level of IF1 was
downregulated under hypoxic conditions. This result was
consistent with the expression of CF6. The codirectional
regulation of ATPase-related subunits may allude to the
influence of hypoxia on energy metabolism and that CF6
has little effect on hypoxic vasoconstriction.
The limitations of this study are as follows. First, our
research lacks three IF1 antagonist interference analyses to

confirm the role of IF1 in PAH. Second, other studies on
the effect of CF6 in hypoxic PAH in rats must be further
investigated. Third, the findings of this study were from rats
and could not be projected completely to human beings.
5. Conclusions
CF6 showed downregulated expression in lung tissue, but
not in the pulmonary vasculature or at the circulation level,
in hypoxia-induced PAH. We speculate that hypoxic stress
from the intratracheal-lung tissue pathway is different
from the MCT-endothelial injury pathway in PAH. This
study provides new insights into CF6 expression and the
pathogenesis of PAH.
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